TY - JOUR T1 - Analysis of 472,688 severe cases of COVID-19 in Brazil showed lower mortality in those vaccinated against influenza JF - medRxiv DO - 10.1101/2021.05.11.21257053 SP - 2021.05.11.21257053 AU - Daniele Melo Sardinha AU - Diana da Costa Lobato AU - Ana Lúcia da Silva Ferreira AU - Karla Valéria Batista Lima AU - Ricardo José de Paula Souza e Guimarães AU - Luana Nepomuceno Gondim Costa Lima Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/14/2021.05.11.21257053.abstract N2 - Objective To analyze the severe cases of COVID-19 in Brazil in 2020 and compare those vaccinated and unvaccinated against influenza in invasive ventilation, admission in Intensive Care Unit (ICU) and deaths.Method Cross-sectional study with public data from the OpenDataSUS platform, regarding confirmed severe cases for COVID-19 in Brazil in the year 2020. Data were analyzed by SPSS, from the chi-square test of independence and binary logistic regression.Results The population was 472,688 cases and 177,640 deaths, with a lethality of 37.58% in severe cases. The test of independence was highly significant in vaccinated survivors (<0.0001), and regression showed an almost twofold odds ratio for invasive ventilation, ICU admission, and death in unvaccinated cases.Conclusion We recommend mass influenza vaccination as an adjuvant in combating the COVID-19 pandemic in Brazil.Competing Interest StatementThe authors have declared no competing interest.Funding StatementConselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPQ Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPESAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:cepAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesopendatasus ER -